Hana Odeh1,2, Lisa Miranda3, Abhi Rao1, Jim Vaught1,4, Howard Greenman5, Jeffrey McLean6, Daniel Reed7, Sarfraz Memon1, Benjamin Fombonne1,2, Ping Guan1, Helen M Moore1. 1. 1 National Cancer Institute , Biorepositories and Biospecimen Research Branch (BBRB), Bethesda, Maryland. 2. 2 Kelly Government Solutions , Rockville, Maryland. 3. 3 Biobusiness Consulting Inc. , Newburyport, Massachusetts. 4. 4 Gray Sourcing , San Diego, California. 5. 5 Provia Laboratories LLC , Littleton, Massachusetts. 6. 6 Leidos Biomedical Research, Inc. , Rockville, Maryland. 7. 7 Wrycan Inc. , Cambridge, Massachusetts.
Abstract
BACKGROUND: Biospecimens are essential resources for advancing basic and translational research. However, there are little data available regarding the costs associated with operating a biobank, and few resources to enable their long-term sustainability. To support the research community in this effort, the National Institutes of Health, National Cancer Institute's Biorepositories and Biospecimen Research Branch has developed the Biobank Economic Modeling Tool (BEMT). The tool is accessible at http://biospecimens.cancer.gov/resources/bemt.asp. METHODS: To obtain market-based cost information and to inform the development of the tool, a survey was designed and sent to 423 biobank managers and directors across the world. The survey contained questions regarding infrastructure investments, salary costs, funding options, types of biospecimen resources and services offered, as well as biospecimen pricing and service-related costs. RESULTS: A total of 106 responses were received. The data were anonymized, aggregated, and used to create a comprehensive database of cost and pricing information that was integrated into the web-based tool, the BEMT. The BEMT was built to allow the user to input cost and pricing data through a seven-step process to build a cost profile for their biobank, define direct and indirect costs, determine cost recovery fees, perform financial forecasting, and query the anonymized survey data from comparable biobanks. CONCLUSION: A survey was conducted to obtain a greater understanding of the costs involved in operating a biobank. The anonymized survey data was then used to develop the BEMT, a cost modeling tool for biobanks. Users of the tool will be able to create a cost profile for their biobanks' specimens, products and services, establish pricing, and allocate costs for biospecimens based on percent cost recovered, and perform project-specific cost analyses and financial forecasting.
BACKGROUND: Biospecimens are essential resources for advancing basic and translational research. However, there are little data available regarding the costs associated with operating a biobank, and few resources to enable their long-term sustainability. To support the research community in this effort, the National Institutes of Health, National Cancer Institute's Biorepositories and Biospecimen Research Branch has developed the Biobank Economic Modeling Tool (BEMT). The tool is accessible at http://biospecimens.cancer.gov/resources/bemt.asp. METHODS: To obtain market-based cost information and to inform the development of the tool, a survey was designed and sent to 423 biobank managers and directors across the world. The survey contained questions regarding infrastructure investments, salary costs, funding options, types of biospecimen resources and services offered, as well as biospecimen pricing and service-related costs. RESULTS: A total of 106 responses were received. The data were anonymized, aggregated, and used to create a comprehensive database of cost and pricing information that was integrated into the web-based tool, the BEMT. The BEMT was built to allow the user to input cost and pricing data through a seven-step process to build a cost profile for their biobank, define direct and indirect costs, determine cost recovery fees, perform financial forecasting, and query the anonymized survey data from comparable biobanks. CONCLUSION: A survey was conducted to obtain a greater understanding of the costs involved in operating a biobank. The anonymized survey data was then used to develop the BEMT, a cost modeling tool for biobanks. Users of the tool will be able to create a cost profile for their biobanks' specimens, products and services, establish pricing, and allocate costs for biospecimens based on percent cost recovered, and perform project-specific cost analyses and financial forecasting.
Authors: Peter H Watson; Sara Y Nussbeck; Candace Carter; Sheila O'Donoghue; Stefanie Cheah; Lise A M Matzke; Rebecca O Barnes; John Bartlett; Jane Carpenter; William E Grizzle; Randal N Johnston; Anne-Marie Mes-Masson; Leigh Murphy; Katherine Sexton; Lois Shepherd; Daniel Simeon-Dubach; Nikolajs Zeps; Brent Schacter Journal: Biopreserv Biobank Date: 2014-02 Impact factor: 2.300
Authors: Fay Betsou; David L Rimm; Peter H Watson; Christopher Womack; Allison Hubel; Robert A Coleman; Liz Horn; Sharon F Terry; Nikolajs Zeps; Brian J Clark; Lisa B Miranda; Robert E Hewitt; Gloria D Elliott Journal: Biopreserv Biobank Date: 2010-06 Impact factor: 2.300
Authors: E Ray Dorsey; Jason de Roulet; Joel P Thompson; Jason I Reminick; Ashley Thai; Zachary White-Stellato; Christopher A Beck; Benjamin P George; Hamilton Moses Journal: JAMA Date: 2010-01-13 Impact factor: 56.272
Authors: Abhi Rao; Jim Vaught; Bill Tulskie; Dorie Olson; Hana Odeh; Jeffrey McLean; Helen M Moore Journal: Biopreserv Biobank Date: 2019-01-14 Impact factor: 2.300
Authors: Lise A M Matzke; Sindy Babinszky; Alex Slotty; Anna Meredith; Tania Castillo-Pelayo; Marianne K Henderson; Daniel Simeon-Dubach; Brent Schacter; Peter H Watson Journal: Biopreserv Biobank Date: 2016-08-30 Impact factor: 2.300
Authors: Natalie T Boutin; Samantha B Schecter; Emma F Perez; Natasha S Tchamitchian; Xander R Cerretani; Vivian S Gainer; Matthew S Lebo; Lisa M Mahanta; Elizabeth W Karlson; Jordan W Smoller Journal: J Pers Med Date: 2022-08-17